



(51) International Patent Classification:

C07D 471/04 (2006.01) **A61P 19/02** (2006.01)
A61K 31/4462 (2006.01)

(21) International Application Number:

PCT/EP2011/056600

(22) International Filing Date:

27 April 2011 (27.04.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1007203.1 29 April 2010 (29.04.2010) GB

(71) **Applicant** (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **ATKINSON, Francis Louis** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **BARKER, Michael David** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **DOUAULT, Clement** [FR/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **GARTON, Neil Stuart** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **LIDDLE, John** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **PATEL, Vipulkumar Kantibhai** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **PRESTON, Alexander George**

[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **WILSON, David Matthew** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

(74) **Agents**: **PRICE, Susanna Clare Hopley** et al.; GlaxoSmithKline, Global Patents (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) **Title**: 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS



(57) **Abstract**: A compound of formula (I) or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast and/or basophil cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, chronic spontaneous urticaria and autoimmune conditions.



-
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*
- Published:**
- *with international search report (Art. 21(3))*